We see a huge potential of the hibernation technology and its benefits for medical needs in blockbuster markets. Currently we are in the final pre-clincal development phase of our SUL-138 compound for the prevention of acute kidney injury. To advance the clinical studies we are raising funds for further development of our compounds.
Who are we?
Sulfateq BV is a privately held company and the company’s shares are held by the founder and an international pool of private investors. Our team has a lot of experience in the medical market and on board are internationally known clinicians who work for the University Medical Hospital clinic (UMCG Groningen) and have extensive experience with clinical trials, especially in kidney diseases. We also keep close contact with a worldwide network of research collaborations including a cooperative research and development agreement (CRADA) with the US Army Institute of Surgical Research. You can read more about our team on this page.
Due to the rapid expansion of the company and developments in the markets we are currently looking for new investors or funding opportunities to develop and expand further.
What is our goal?
Our main focus is the development of SUL-138 for the prevention of Acute Kidney Injury (AKI) and ultimately to license and/ or sell the product to pharmaceutical companies. Acute Kidney Injury is the sudden loss of kidney function and it affects more than 1.2 million people each year in the United States alone. It occurs in different situations and is particularly frequent in patients hospitalized for major surgery, including cardiac and/or vascular surgery, trauma, infection, cardiac disease or cancer. At this moment there is no therapy or drugs available for the protection against AKI during major surgery and we see huge potential for the hibernation technology and its benefits for AKI. We have conducted successful animal studies using SUL-compounds to inhibit the occurrence of kidney injury following damage. With the SUL-138 compound it is possible to protect the kidney. The SUL-138 compound is engaged in final pre-clinical development, i.e. safety pharmacology. After the pre-clincal phase we will follow the usual development procedure in the pharmaceutical industry: Phase I, Phase II and Phase III, registration and finally market introduction. To advance this proces we are seeking investors who want to help us with achieving our goals.
There are no therapies or drugs available to prevent or treat AKI. Each year, approximately 700,000 deaths in Europe, the US and Japan are associated with AKI. Annually, hospital-acquired AKI affects approximately 2 million patients in the Western World and the incidence is rising every day. The disease occurs in as many as 4% of hospital admissions and up to 40% of admissions to intensive care units.
The main benefits of SUL-138 for AKI prevention are:
- Improve survival rate of major surgery
- Reduce days spent in ICU & days spent in hospital
- Prevention of the need for renal replacement therapies (e.g. dialysis)
Moreover, SUL-138 also has multiple applications in other therapeutic areas such as drug development for COPD and obesity/diabetes II but also prolonged storage of organs and human blood platelets.
What can we offer you?
We offer a great opportunity for investing in a breakthrough solution for the prevention of Acute Kidney Injury. If you share the same enthusiasm for the possibilities of hibernation in healthcare and its huge potential, please contact us for more information about investment possibilities or fill in our contact form and we will contact you as soon as possible. We are looking forward doing business with you!
- Read more about hibernation in life sciences
- Read more about the mechanism-of-action of our compound
- Read more about preventing acute kidney injury
- Download information brochure